Drug Profile
Herceptarg - Roche
Latest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator Roche
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 05 Sep 2023 Discontinued - Preclinical for Cancer in Switzerland (Parenteral)
- 28 May 2020 No recent reports of development identified for preclinical development in Cancer in Switzerland (Parenteral)
- 16 Apr 2016 Preclinical trials in Cancer in Switzerland (Parenteral)